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Cancer cells and stem cells share a number of biolog-
ical characteristics including abundant amounts of
decondensed chromatin. However, the molecular cor-
relates and the factors involved in altering chromatin
structure in cancer cells are not well known. Here, we
report that less differentiated stem-like cells in the
basal compartment of human and mouse prostate
contain lower levels of the polycomb heterochroma-
tin marker H3K27me3 than more differentiated lumi-
nal cells. This link to differentiated normal cells is
also found in a number of other human and rodent
tissues characterized by hierarchical differentiation.
In addition to MYC’s traditional role as a gene-spe-
cific transcription factor, recent studies indicate
that MYC also affects global chromatin structure
where it is required to maintain “open” or active
chromatin. We now demonstrate that in both MYC-
driven prostate cancers in mice and human pros-
tate cancers, global levels of H3K27me3 are reduced
in prostatic intraepithelial neoplasia and invasive
adenocarcinoma lesions. Moreover, decreased levels
of H3K27me3 correlate with increased markers of
disease aggressiveness (eg, Gleason score and patho-
logical stage). In vitro, experimentally forced reduc-
tions in MYC levels result in increased global levels of
H3K27me3. These findings suggest that increased lev-
els of decondensed chromatin in both normal pro-
genitor cells and cancer cells are associated with
global loss of H3K27me3, which is linked to MYC
overexpression. (Am J Pathol 2012, 181:560–569; http://
dx.doi.org/10.1016/j.ajpath.2012.04.021)
560Cancer cells and embryonic stem cells (ESCs) share a
number of biological features including a block in termi-
nal differentiation and the capacity for unlimited self-re-
newal. One potential link between stem cells and cancer
is the potent oncogeneMYC. MYC is a sequence-specific
transcription factor that is overexpressed in up to 70% of
all human cancers and regulates a large number of cel-
lular processes, including DNA replication, ribosome bio-
genesis and mitochondrial function.1 MYC is required for
embryonic development as well as maintenance of ESC
self-renewal.2,3 Further, MYC is one of four genes re-
quired for efficient epigenetic reprogramming of adult
differentiated cells into induced pluripotent stem cells
(iPSCs),4,5 which share virtually all of the biological prop-
erties of ESCs. Additionally, many human cancers ex-
press transcriptional programs that are characteristic of a
“MYC” signature, and this signature is highly active in
ESCs.6–8
In addition to the classical view that MYC functions pri-
marily by controlling the transcription of specific genes,
another feature that appears to link MYC to stem cells and
cancer cells is its ability to regulate global chromatin struc-
ture.9 It is well known that stem cells and progenitor cells
are characterized by an “open” conformation that con-
sists predominantly of decondensed euchromatin with
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family members can regulate global chromatin openness
and accessibility. For example, Knoepfler et al11 found
that deletion of Nmyc (alias N-myc) in developing cere-
bellar granule neural progenitors (CGNPs) resulted in
loss of open chromatin and a premature nuclear chroma-
tin condensation. These changes were characterized by
decreased levels of acetylation of histones H3 and H4,
modifications generally associated with open and active
chromatin. In terms of histone tail methylation, Knoepfler
et al found that Nmyc-null CGNPs exhibited high levels of
H3K9me2 and H3K9me3, both of which are associated
with repressive heterochromatin, and a reduction in
H3K4me3, which is associated with active euchroma-
tin.11 These findings, along with other recent genome-
wide studies, which document widespread MYC binding
and influence on global levels of histone modifications,
support the emerging concept that a novel mechanism
by which MYC overexpression can influence cellular
properties involves changes to overall chromatin organi-
zation and structure.3,12,13
It has been well known that many cancer types contain
a relatively large fraction of cells that possess decon-
densed “open” or “vesicular” chromatin, and this feature
is often helpful in establishing the diagnosis of cancer by
pathologists.14,15 Prostate cancer develops from intraepi-
thelial lesions referred to as prostatic intraepithelial neo-
plasia (PIN). PIN and prostate cancer cells, like many
other cancer types, are characterized by enlarged nuclei
with increased amounts of decondensed “open” chroma-
tin and prominent enlarged nucleoli.16–18 Recently, it has
become clear that in addition to MYC’s long-suspected
role in prostate cancer progression (as a result of gain of
chromosome 8q24), human PIN, and cancer lesions very
commonly overexpress MYC protein even in the absence
of 8q24 gain.19,20 Further, in transgenic mice programed
to overexpress MYC in the prostate, the onset of MYC
overexpression corresponds precisely with the onset of
nuclear enlargement, nucleolar enlargement, increased
numbers of nucleoli, and global chromatin decondensa-
tion.16 Given MYC’s new and unexpected role in influenc-
ing global chromatin structure, we have begun to inves-
tigate whether the extent of global levels of well-studied
posttranslational histone modifications within chromatin
are altered during prostatic carcinogenesis and whether
MYC overexpression results in alterations in global levels
of such modifications in human and mouse prostate PIN
and cancer lesions.
One well-known posttranslational modification of his-
tone tails that is tightly regulated in development and
during ESC differentiation is the polycomb mark trimethy-
lation of histone H3 on lysine 27 (H3K27me3). This mark
is generally associated with transcriptional repression, a
closed heterochromatic structure, and dysregulation in a
number of cancers. For example, in myelodysplastic syn-
drome,21 recent studies have identified inactivating mu-
tations in the H3K27me3 methyltransferase enhancer of
zeste homolog 2 (EZH2), which is the catalytic subunit of
the polycomb repressive complex 2 (PRC2). Although
global levels of H3K27me3 have not been previously
studied in the setting of EZH2 mutations in myelodysplas-tic syndrome, the presence of EZH2 mutations suggests
that loss of H3K27me3, perhaps in specific loci, is impor-
tant in this disease.22 EZH2 mutations also occur in some
diffuse large cell lymphomas, as well as some follicular
lymphomas, and in these diseases, it remains somewhat
controversial whether the mutations are inactivating or
activating.23–25 In contrast to these results suggesting
that EZH2 functions as a tumor suppressor in myelodys-
plastic syndrome, and unclear results in lymphoma,
EZH2 has been shown more clearly to have an oncogenic
role in a number of other cancer types. For example,
overexpression of wild-type EZH2 has been documented
in breast and prostate cancer.26–28 Further, forced over-
expression of EZH2 can transform prostatic epithelial
cells in vitro29; forced reductions in EZH2 decrease pros-
tate and breast cancer cell proliferation.26,28,30,31 Fur-
thermore, a PRC2 target gene signature is predictive of
poor outcome in prostate cancer.23
Despite an apparent increase of H3K27me3 in the
promoter regions of specific genes in prostate and breast
cancer, reductions in global levels of H3K27me3 have
been reported to occur in cancers of the breast, pan-
creas, ovary, and kidney, as compared to levels found in
their normal tissues.32,33 However, there is still much to be
learned about the global levels of H3K27me3 and about the
mechanisms by which these levels can become altered
during normal differentiation and carcinogenesis. In the
present study, we used immunohistochemical (IHC) and
multilabel immunofluorescent staining to probe global
H3K27me3 levels in various normal human and mouse
tissue samples, in human prostate cancer and precursor
lesions, as well as in MYC-driven mouse PIN and adeno-
carcinoma lesions. Further, to begin to gain mechanistic
insights into regulation of global H3K27me3 levels, we
asked whether forced reductions in MYC resulted in
changes in global H3K27me3 levels.
Materials and Methods
Western Blot Analysis
For Western blotting of non-histone proteins, cells were
lysed in radioimmunoprecipitation assay buffer. Lysates
were then centrifuged at 14,000  g for 10 minutes at
4°C. For Western blotting of histone proteins, cells were
lysed in triton extraction buffer then dialyzed into 0.01
mol/L trichloroacetic acid (yield: purified histone pro-
teins). Proteins were electrophoresed and transferred to
nitrocellulose membranes for immunoblotting. Mem-
branes were probed with the antibodies as follows: MYC
(#1472-1, 1:5000 dilution; Epitomics, Burlingame, CA);
tubulin (CP06, 1:2000; Calbiochem, Gibbstown, NJ); his-
tone H3 (#39163, 1:10,000 dilution; Active Motif, Carls-
bad, CA); H3K27me3 (#39155, 1:2000 dilution; Active
Motif); and androgen receptor (AR) (sc-816, 1:2000 dilu-
tion; Santa Cruz Biotechnology, Santa Cruz, CA). The
blots were quantitatively analyzed using the Odyssey
Infrared Imaging System (LI-COR Biosciences, Lincoln,
NE) and R statistics package.
562 Pellakuru et al
AJP August 2012, Vol. 181, No. 2Immunohistochemistry
Immunohistochemistry was performed using the Power
Vision Poly-HRP IHC Kit (ImmunoVision, Springdale,
AZ). Slides were steamed for 40 minutes in EDTA solution
(Zymed Laboratories/Invitrogen, Carlsbad, CA) and incu-
bated with rabbit polyclonal anti-histone H3 antibody (1:
4000 dilution) for 45 minutes, rabbit polyclonal anti–c-
MYC antibody (1:300) overnight at 4°C, or mouse
monoclonal anti-H3K27me3 (ab6002, 1:200; Abcam,
Cambridge, MA) overnight at 4°C. Poly-HRP–conjugated
anti-mouse/rabbit IgG antibody was used as secondary
antibody. Staining was visualized using 3,3=-diaminoben-
zidine (Sigma, St. Louis, MO), and slides were counter-
stained with hematoxylin.
Immunofluorescence
Pretreatment conditions and primary antibody dilutions
for histone H3 and H3K27me3 were the same as for
immunohistochemistry. Slides were incubated with rabbit
polyclonal cytokeratin 5 antibody (PRB-160P, 1:15000;
Covance, Princeton, NJ) for 45 minutes. The immuno-
complexes were labeled with secondary antibodies con-
jugated with Alexa 488 or Alexa 568 dyes (Invitrogen),
and nuclei were counterstained with DAPI. Slides were
visualized using a Nikon E400 fluorescence microscope
(Nikon Instruments, Melville, NY).
Cell Culture
The human prostate cancer cell lines LNCaP, DU145,
and PC3 and the human breast cancer cell line MCF7
were obtained from the ATCC (Rockville, MD). p493 cells
were a generous gift from Chi Van Dang (Johns Hopkins,
Baltimore MD). All cells were maintained at 37°C and 5%
CO2, and supplemented with RPMI 1640 or Dulbecco’s
modified Eagle’s medium with 10% serum.
Transfections
Cells were transfected using Oligofectamine or Lipo-
fectamine 2000 (Invitrogen). Pools containing four small-
interfering RNA (siRNAs) against MYC (L-003282; Dhar-
macon, Lafayette, CO) or against AR (L-003400;
Dharmacon) were transfected at a final concentration of
50 nmol/L. As a control in each transfection experiment,
cells were transfected with siCONTROL Non-Targeting
siRNA Pool #1 (D-001810; Dharmacon).
Tissues and Tissue Microarrays
This study was approved by the Johns Hopkins Univer-
sity School of Medicine institutional review board. TMAs
were constructed and evaluated as described.19
Analysis of Immunohistological Staining
Each scanned image from the TMAs was re-diagnosed
by B.G., and regions of interest were demarcated forsemiquantitative image analysis using FrIDA as de-
scribed.19 Briefly, for brown staining, we determined the
median intensity of staining as well as the area of nuclear
staining. Since H3K27me3 IHC staining was localized
exclusively to nuclei, we derived the percentage of nu-
clear area staining in regions of interest by dividing the
total area of brown staining by the total area of brown plus
blue (hematoxylin) staining. We also derived an
H3K27me3 score by summing all brown staining in the
region of interest and dividing that by the area of brown
plus blue staining. Statistical analyses for TMA data were
performed using R.
Results
H3K27me3 Levels Are Reduced in
Stem/Progenitor Cell Compartments
in Multiple Human and Mouse Tissues
Normal prostatic epithelial cells generally showed intense
positive staining for H3K27me3 in nuclei within the lumi-
nal compartment. Conversely, basal cells (highlighted by
keratin 5 staining in Figure 1, A–D), which are thought to
be stem-like cells and known to be less differentiated
than luminal cells,34,35 showed markedly less staining for
H3K27me3 than the luminal cells. Staining for total H3
protein showed similar levels in prostate basal and lumi-
nal cells (Figure 1, E–H; see also Supplemental Figure S1
at http://ajp.amjpathol.org), indicating that the difference
in basal cell versus luminal cell staining for H3K27me3 is
likely not the result of antigen inaccessibility to the anti-
body. Also, levels of H3K4me3, generally known as an
activation mark found predominantly in euchromatin, also
did not appear different between basal versus luminal
cells (not shown). These results indicate that H3K27me3
levels correlate with differentiation in the human prostate.
Similar results showing strong luminal cell staining and
weak basal cell staining were seen in the mouse prostate
(Figure 2, A and B).
To determine whether global H3K27me3 levels corre-
late with cellular differentiation status beyond the pros-
tate, we performed immunostaining across a variety of
normal tissues. Interestingly, rapidly renewing epithelial
tissues that display hierarchical differentiation were gen-
erally found to have H3K27me3 staining patterns that
correlated directly with increasing degrees of differentia-
tion. Crypts in the small intestine and colon (Figure 3, A
and B), where stem cells are localized, showed little to no
H3K27me3, whereas the cells in the more differentiated
areas toward the luminal surface showed higher amounts
of H3K27me3 staining. Similarly, in the mouse tongue,
which is characterized by a stratified squamous epithe-
lium, H3K27me3 levels were higher in the more differen-
tiated cells toward the surface as compared to the stem-
like cells in the basal compartment (Figure 3C).
Conversely, in tissues that do not rapidly renew and that
do not show hierarchal differentiation patterns (eg, kid-
ney, liver, pancreas, lung, salivary gland, thyroid; see
Supplemental Figure S2, A–F, at http://ajp.amjpathol.org),
there was little variation in H3K27me3 staining levels ac-
ells (ar
l and ba
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there was low staining in the germinal center of lymphoid
tissue in the tonsil (see Supplemental Figure S2F at http://
ajp.amjpathol.org). Similar findings of generalized in-
creases in H3K27me3 with differentiation in tissues show-
ing rapid turnover and hierarchical differentiation, with
more homogeneous staining in tissues without apparent
hierarchical differentiation, were found in both mouse and
rat tissues (not shown). Taken together, these data indi-
cate that H3K27me3 staining levels correlate with the
degree of differentiation/maturation across a number of
organ systems and suggest the potential for H3K27me3
staining to serve as a biomarker of terminal differentiation
(eg, increasing levels of staining occur as cells differen-
tiate/mature).
H3K27me3 Levels Are Reduced in
Inflammation-Associated, Preneoplastic,
and Neoplastic Lesions of the Prostate
We next examined H3K27me3 staining in different pros-
tatic lesions using tissue microarrays (Tables 1 and 2). A
subset of prostatic atrophy lesions have been shown
Figure 1. H3K27me3 levels correlate with differentiation in human prostati
cytokeratin (keratin 5) shows a decrease in levels of H3K27me3 in basal c
independent of levels of total histone H3 as they are similar in both lumina
Figure 2. H3K27me3 levels are reduced in mouse MYC-driven PIN lesions.
As compared to normal mouse prostate (A), H3K27me3 levels are reduced in
mouse PIN lesions (B). Arrows indicate luminal cells. Arrowheads indicate
basal cells. Original magnification, 400.previously to harbor some of the characteristic molecular
alterations of PIN and prostatic adenocarcinoma includ-
ing hypermethylation of the GSPT1 upstream promoter/
CpG island; these lesions have been found in association
with PIN and early adenocarcinoma lesions.36 Interest-
lium. A–D: Immunofluorescence (IF) staining of H3K27me3 and a basal cell
rowheads) as compared to luminal cells (arrows). E–H: This decrease is
sal cells. Nuclei are counterstained with DAPI.
Figure 3. H3K27me3 levels correlate with differentiation in numerous tis-
sues. Immunohistochemical staining of human small intestine (A) and colon
(B) demonstrating that H3K27me3 staining is very low in the crypts, which
harbor the stem-like and less differentiated cells, and increases in the more
differentiated cells toward the lumen. Original magnification, 200. C: This
observation is also seen in mouse tissues including the mouse tongue (orig-
inal magnification, 400). Less differentiated basal-most cells show muchc epitheweaker staining for H3K27me3 as compared to more mature cells closer to
the surface (top of image).
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tatic atrophy lesions in which a fraction of the cells ex-
press both “basal cell–specific” and luminal-enriched
keratins at high levels as well as variable levels of differ-
entiation markers such as NKX3.1, AR, and prostate-
specific antigen (PSA). Thus, these lesions are enriched
for cells possessing a phenotype intermediate between
basal and luminal cells (Figure 4, A–F, Table 2). Our
chromogenic image analysis approach allows us to ex-
amine both the intensity of staining (median intensity was
used) as well as the area of staining within given tissues.
In atrophy, although the overall area of staining was sig-
nificantly reduced compared to normal epithelium (ie,
area of brown nuclear staining over total nuclear area),
the median intensity of those cells staining positively was
not significantly reduced.
Strikingly, most cases of prostatic intraepithelial neo-
plasia (PIN), which is considered a key direct precursor
to human prostatic adenocarcinoma, showed markedly
reduced immunostaining in many of the neoplastic lumi-
nal cells as compared with benign, normal-appearing
luminal cells from the same cases (Figures 4 and 5). In
PIN, both the median intensity and area of staining were
Table 1. Pathological Features of Radical Prostatectomy Cases
Used in This Study on TMAs
Gleason score
Pathological stage
T2 T3A T3B Total
5 to 6 39 9 1 49
7 9 21 14 44
8 to 9 4 26 31 61
Total 52 56 46 154
Fisher’s exact test, P  0.001.
Table 2. Histopathology of TMA Scores Evaluated by Automated
Histologic type
No. of TMA
cores
(patients, n)
Median
H3K27me3
intensity
Normal/benign
Normal prostatic epithelium 346 (116) 162.2
Atrophy
Simple atrophy 116 (28) 164
Simple atrophy with cyst
formation
4 (4) 176.5
Post-atrophic hyperplasia 8 (5) 163.2
Total atrophy 128 (29) 164
PIN
High grade 61 (22) 154
Mixed high and low grade 7 (6) 155
Low grade 13 (13) 156
Total PIN 81 (29) 154.4
Carcinoma
Adenocarcinoma, Gleason 3 64 (45) 147.4
Adenocarcinoma, Gleason 4 68 (58) 138.4
Adenocarcinoma, Gleason 5 12 (11) 135.9
Total carcinoma 144 (108) 143.4
Metastatic carcinoma 67 (67) 138.2
Total 766 (154)
Cores with nondiagnostic tissue or cases with only stromal tissue on
*Kruskal-Wallis equality of populations rank test compared to normal prostate
NA, not applicable.reduced. Interestingly, the PIN cells located most closely
to the basement membrane tended to show less staining
for H3K27me3 than cells located toward the tips of pa-
pillae toward the lumen.
We next examined prostatic adenocarcinoma lesions
and found reduced staining, as compared to normal
matched luminal cells, in the majority of cases (Figures 4
and 5). Most carcinomas showed variable staining with
some cells staining strongly positive and others with re-
duced and markedly reduced staining. Despite this vari-
ability, there was a progressive decrease in both median
intensity and area of nuclear staining with increasing
Analyses for H3K27me3 Staining
ue*
Median
H3K27me3
nuclear area ratio P value*
Median
H3K27me3
score P value*
0.716 NA 114.16 NA
0.440 0.0001 71.49 0.0001
0.296 0.0143 54.21 0.0280
0.683 0.1334 107.11 0.2389
0.454 0.0001 72.27 0.0001
01 0.655 0.0001 101.17 0.0174
0.539 0.0007 80.47 0.0005
0.560 0.0064 84.13 0.0010
01 0.620 0.0015 96.14 0.0004
01 0.804 0.0007 113.71 0.8829
01 0.653 0.0774 91.24 0.0001
01 0.434 0.0053 62.34 0.0006
01 0.733 0.8035 101.36 0.0003
01 0.478 0.0001 66.26 0.0001
spot were not used for the analysis.
Figure 4. H3K27me3 levels are reduced in atrophy, PIN, and cancer. Rep-
resentative immunohistochemical staining of normal prostate tissue (A and
D) (arrows indicate normal epithelium), focal atrophy (B), and PIN (C).
Note decreased staining atrophy and PIN compared with normal. Staining in
primary carcinoma (E) and a lymph node metastasis (F) shows decreased
staining for H3K27me3 in the tumor tissue as compared to the normal
(arrows indicate carcinoma). D and E are from the same patient. Original
magnification, 200.Image
P val
NA
0.11
0.13
0.93
0.08
0.00
0.19
0.02
0.00
0.00
0.00
0.00
0.00
0.00
the TMA
epithelium using grouped values.
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son pattern 3 tended to show reduced staining intensity
as compared to normal epithelium, but not reduced area
of nuclear staining, which in fact was significantly higher
than normal (Table 2). The median IHC score, which rep-
resents a sum of the intensities for cells in a given lesion
divided by the total nuclear area, was also not significantly
reduced in Gleason pattern 3 adenocarcinoma lesions.
Hormone-naive metastatic prostate cancer lesions also
show reduced H3K27me3 staining, both in median intensity
and area, comparable to that of the higher-grade primary
cancer lesions (Figures 4 and 5, Table 2). Staining of a
number of prostatic adenocarcinomas for either total H3 or
total H3K4me3 revealed no apparent differences between
the intensity and area of staining as compared with normal
prostatic epithelium (not shown).
H3K27me3 Levels Are Independent of EZH2
Expression in Vivo
EZH2 is known to be overexpressed in prostate cancer.
However, by immunofluorescence, we found that levels
of H3K27me3 did not correlate with levels of EZH2 in
several tissues (see Supplemental Figure S3, A–D, at
http://ajp.amjpathol.org). The difference was especially
noticeable in lymphoid nodules within tonsil tissue, in
which there was an apparent inverse correlation between
EZH2 and H3K27me3 with minimal colocalization. In the
prostate, areas of EZH2 overexpression did not coinci-
dence with areas of high H3K27me3 levels as might be
expected. The same, nearly inverse pattern was seen in
colon and skin. This observation indicates that levels of
H3K27me3 are not linked to EZH2 protein expression.
Regulation of Global Changes in Histone
Modifications by MYC
We next examined whether the observed alterations in
global H3K27me3 content may be caused by MYC acti-
vation, which is known to globally alter heterochromatin
states. To examine this in vivo, we turned to mice that
overexpress MYC in the prostate. Lo-MYC and Hi-MYC
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Figure 5. Quantification of immunohistochemistry on TMAs. H3K27me3
levels inversely correlate with worsening disease, in which metastatic and
high-grade tumors show the lowest levels of H3K27me3.mice characteristically develop PIN that progresses tocribriform PIN/intraductal carcinoma and then to local-
ized invasive adenocarcinoma lesions.16,37 Strikingly,
levels of H3K27me3 were markedly reduced in mouse
PIN (Figure 2), cribriform PIN, and adenocarcinoma le-
sions (not shown) as compared to matched normal lumi-
nal epithelial cells. These results support the hypothesis
that MYC overexpression results in decreases in global
H3K27me3 levels in prostatic luminal epithelial cells in
vivo, concomitant with the morphological appearance of
PIN. Further, like their human counterparts, mouse pros-
tatic PIN and carcinomas are characterized by reduced
H3K27me3 levels.
To further examine the effects of MYC on global
H3K27me3 levels and the potential cell context spec-
ificity of its effects, we experimentally manipulated lev-
els of MYC in a number of cancer cell lines. Changes in
overall H3K27me3 levels were determined by quanti-
tative Western blotting in which we calculated the nor-
malized ratio of H3K27me3 (normalized to total H3) in
cells treated with anti-MYC siRNA to cells treated with
a nontargeting scrambled siRNA in the same experi-
ment. In PC3 (androgen receptor–negative prostate
cancer cell line) as well as in LNCaP (androgen recep-
tor–positive and androgen-sensitive prostate cancer
cell line) cells, MYC knockdown by siRNA resulted in
an increase in overall H3K27me3 levels (Figure 6,
A–E). Similar results were seen in the MCF7 breast
cancer cell line. Further, using a B-cell Burkitt’s lym-
phoma cell line (p493) engineered to silence MYC
expression by addition of tetracycline (tet-off cells),
H3K27me3 levels were increased after MYC levels
were reduced on tetracycline addition (Figure 6E). In-
terestingly, the effects of MYC levels on global
H3K27me3 did not occur in all lines tested; DU145
cells (androgen receptor–negative prostate cancer cell
line) did not show increased global levels of
H3K27me3 after MYC knockdown (Figure 6F). This was
not due to variations in baseline levels of MYC, as
DU145 cells and LNCaP show similar levels of MYC
(Figure 6E).
Furthermore, to determine whether AR may play a
role in LNCaP cells, we manipulated levels of AR with
siRNA in the same manner that we manipulated levels
of H3K27me3. There was no change in levels of
H3K27me3 with changes in levels of AR (see Supple-
mental Figure S4, A and B, at http://ajp.amjpathol.org).
Furthermore, we performed immunohistochemistry on
C4-2b and CWR22Rv1—castrate-resistant—cell lines
as well as the LNCaP—androgen-sensitive—cell line
(see Supplemental Figure S5, A–C, at http://ajp.
amjpathol.org). In this model of prostate cancer progres-
sion, the castrate-resistant cell lines did not show altered
levels of H3K27me3 as compared to the non–castrate-re-
sistant lines. Therefore, this phenomenon of decreased
H3K27me3 levels is independent of AR but not of MYC.
Thus, although the effect does not occur in all cells, MYC
can induce global changes in levels of H3K27me3 in a
number of different cancer cell types, as well as in mouse
luminal epithelial cells in vivo.
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We report that the normal human and mouse prostates
are characterized by increased levels of H3K27me3 in
more differentiated luminal cells as compared to the less
differentiated stem-like basal cells. This link to the differ-
entiated state of normal cells was also found in a number
of other human and rodent tissues that are characterized
by rapid tissue renewal and hierarchical differentiation.
Further, in both MYC-driven prostate cancers in mice and
in clinical human samples, we found that global levels of
H3K27me3 are reduced in both PIN and invasive adeno-
carcinoma lesions. Finally, we showed that in prostate
cancer cells, breast cancer cells, and lymphoma cells,
experimentally forced reductions in MYC levels resulted
in increased global levels of H3K27me3. These results
provide: i) evidence that global levels of H3K27me3 are
deregulated (eg, reduced) early during prostatic carci-
nogenesis; ii) evidence that H3K27me3 global levels
Figure 6. siRNA knockdown of MYC results in increased levels of H3K27me3.
A serial dilution series (factor of 2) for H3K27me3 (A) and total histone H3 (B)
with histone protein from PC3 prostate cancer cells show the linear range for
each antibody (C and D) respectively. E: Representative Western blots show a
siRNA knockdown of MYC protein for two different cell lines as well as baseline
levels of MYC in all five cell lines. F:MYC knockdown results in increased levels
of H3K27me3 in MCF7 (Student’s t-test, P  0.05), PC3 (P  0.05), p493 (P 
0.05), and LNCaP (P  0.05) cell lines, but not in DU145 cells (P  0.05),
suggesting the effect is context specific.track with cellular differentiation in vivo; iii) evidence thatat least one mechanism for H3K27me3 deregulation in
prostate and breast cancer results from overexpression
of MYC; iv) support for the concept that MYC influences
global chromatin structure during the process of neoplas-
tic transformation of prostatic luminal epithelial cells; and
v) additional evidence to support the concept that MYC
overexpression blocks epithelial cell differentiation in PIN
and prostatic adenocarcinomas.38
Our main assessment was based on immunohisto-
chemical and immunofluorescent staining. Although it is
possible that reduced staining for H3K7me3 in luminal
cells of the prostate, PIN, and carcinoma could relate to
lack of access to the antibody, it is noteworthy that the
cell types that showed a clear differential in staining for
H3K27me3 showed no difference in staining for the total
H3 protein in multilabel immunofluorescent assays. Since
the antibody specificity in Western blots appeared to be
very high, we conclude that these results are indicative of
lower levels of H3K27me3 in basal cells, PIN cells, and
carcinoma cells as compared to normal-appearing lumi-
nal cells. Similar results were obtained in both mouse and
human tissues, including the difference in basal versus
luminal in normal, differentiating cells across many organ
systems with hierarchical differentiation, MYC-driven
mouse prostate precursors, and invasive lesions.
Although our results suggest that at least one mecha-
nism by which H3K27me3 global levels are regulated
involves MYC, it is not clear whether physiological levels
of MYC are responsible for the pattern of global
H3K27me3 staining observed in normal tissues. This is at
least plausible; although we did not examine this ques-
tion in the current study, it is known that endogenous
MYC levels are higher in stem cell compartments of both
intestinal epithelium39 and squamous epithelium of the
skin,40 and MYC levels fall in these tissues as the cells
differentiate/mature. Not much is known about the dy-
namics of global levels of H3K27me3 and normal cellular
differentiation. Interestingly, a study that mapped ge-
nome-wide occupancy of promoter sites in epidermal
keratinocytes found that H3K27me3 marks disappear in a
number of epidermal gene promoters concomitant with
their induction of expression.41 However, this study did
not examine overall global levels of H3K27me3.
The changes in overall levels of H3K27me3 were quan-
titatively assessed by Western blot analysis after forced
reductions in MYC in cell culture, as well as semiquanti-
tatively by chromogenic IHC and image analysis on tis-
sues. The results of the Western blot studies, which were
carefully quantified using assays performed within the
linear range, showed an approximately 20% to 50% in-
crease in H3K27me3 levels after MYC knockdown. Inter-
estingly, although IHC is not truly linear, the magnitude of
change found by our image analysis of the IHC staining
was consistent with those observed in more quantitative
Western blots. Intriguingly, Haffner et al42 recently re-
ported a highly similar pattern of overall staining for 5-hy-
droxy-methyl cytosine (5-HMC) in human tissues and
cancer specimens, suggesting that H3K27me3 and
5-HMC levels may track together.
Our findings might relate to others in terms of onco-
gene and/or tumor suppressor gene alterations resulting
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ined here. Transformation of rat fibroblasts by Ras re-
sulted in a less condensed chromatin structure.15 Fur-
ther, recent work has shown that loss of the tumor
suppressor gene, BRCA1, also results in reduced
amounts of condensed heterochromatin in both mouse
tumors and human cancer cells.43 Interestingly, loss of
BRCA1 function resulted in derepression and ectopic
expression of satellite DNA, and the resultant RNA tran-
scripts lead to DNA damage, cell cycle checkpoint de-
fects, and genomic instability.43 These findings suggest
that decondensation of heterochromatin may be a com-
mon feature associated with a number of disparate on-
cogenic events (eg, Ras activation, MYC overexpression,
and BRCA1 loss). Further, at least in the case of loss of
BRCA1, this appears to have profound functional rele-
vance in the neoplastic process. Although we have not
determined whether MYC overexpression results in dere-
pression of satellite DNA in mouse or human cells, our
preliminary data show changes in MYC-induced PIN le-
sions in the prostate in vivo as characterized by wide-
spread reorganization of foci staining for histone
H3K9me3, which is known to be associated with DAPI
foci (T. Iwata, L. Pellakuru, A.M. De Marzo, unpublished
observations). Thus, these results imply that oncogenic
alterations in a number of different cancer genes result in
alterations in heterochromatin structure, with a general
theme emerging of alterations in chromatin condensation in
cancer as compared to normal cell counterparts.15 These
pervasive findings in cancer may indeed correlate with
changes and increased levels of decondensed chromatin,
routinely visualized by anatomic pathologists in diagnostic
H & E–stained slides dating back well over 100 years.
Although there is experimental evidence that basal
cells are the direct precursor cells for cancer cell forma-
tion in the prostate44 there are other observations and
experimental evidence to suggest that intermediate lumi-
nal cells, rare stem-like luminal cells called CARNS,45 or
perhaps even mature normal luminal cells can be the
targets of transformation in the prostate.16,19,20,46 In the
present study, we found that both basal cells and inter-
mediate cells, which are enriched in regions of focal
prostatic atrophy, show reduced H3K27me3 staining as
compared to mature luminal cells. Although these results
do not shed light on the cell of origin per se, it is of interest
that basal cells and intermediate cells, which are both
clearly less differentiated than luminal cells (eg, less AR,
NKX3.1, PSA in humans, etc), share the feature of re-
duced H3K27me3 with PIN cells (which have a luminal-
like phenotype) and prostate cancer cells.
Our findings raise a number of interesting questions
that require additional clarification in future studies. For
example, since MYC overexpression also causes up-
regulation of EZH2,30 and EZH2 is up-regulated in pros-
tate cancer and other cancers, it is currently unclear why
global levels of H3K27me3 are decreased by MYC over-
expression and decreased in prostate cancer and PIN. A
recent report by Hyland et al47 indicated that transduction of
keratinocytes transduced with human papillomavirus
type-16 E6/E7 genes resulted in an increase in EZH2
levels and a decrease in global levels of H3K27me3.These authors suggested that whereas EZH2 protein was
overexpressed, as a result of increased phosphorylation
of serine 21 on EZH2, there was likely reduced EZH2
methyltransferase activity. Hyland et al found down-reg-
ulation of PRC1 components, as well as increased levels
of KDM6A, a histone lysine demethylase, all of which can
lead to reduced H3K27me3. Finally, in human squamous
intraepithelial neoplasia, a precursor to invasive squa-
mous cell carcinoma, there were reduced levels of
H3K27me3,47 similar to what we report here in PIN le-
sions. Although we have recently shown that MYC over-
expression in prostate cancer results in increased EZH2
mRNA and protein levels, we did not measure EZH2
histone lysine methyltransferase activity or phosphoryla-
tion of serine 21 of EZH2.30 We performed immunohisto-
chemistry on various tissues, and we show that levels of
H3K27me3 do not vary directly with EZH2; in fact, they
seem to vary inversely as can been seen clearly in tonsil.
In other tissues, there is very little coexpression of EZH2
and H3K27me3, indicating that levels of H3K27me3 may
be independent of EZH2 expression, supporting the con-
clusions of Hyland et al. Thus, the precise mechanisms
by which MYC overexpression leads to decreased global
levels of H3K27me3 await future studies, including
whether MYC affects expression or activity of histone 3
lysine 27 demethylases in prostate cancer. Another ques-
tion is what is the nature of the context-specific finding
whereby forced reductions of MYC result in increased
H3K27me3 levels in some prostate cancer and breast
cancer cells, but not in other prostate cancer cells in
vitro? What functional modules of MYC protein are re-
quired for affecting H3K27me3 levels? What other histone
marks are affected by MYC in a global fashion in prostate
cancer and PIN cells? How do these findings of reduced
levels of a repressive histone mark correlate with previ-
ously reported reduced levels of a number of histone
activation marks in prostate cancer?48
In summary, we show that a key marker of at least
some types of heterochromatin, the polycomb repressive
mark, H3K27me3, increases in many lineages in vivo as
cells differentiate. Further, H3K27me3 is markedly re-
duced in prostate cancer cells, and this reduction occurs
at the precursor lesion stage in prostate cancer (eg, PIN),
correlates with markers of disease aggressiveness, is
retained into advanced phases of the disease, and is
regulated at least in part by MYC. These studies provide
potential new mechanistic insights into a long-standing
observation whereby PIN and prostate cancer cells show
widespread decondensation of chromatin.
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